News & media

Submissions in response to the Office of Drug Control's (ODCs) Consultation on Single Licence Model close COB Monday 3 February 2020.

The Office of Drug Control is implementing the 26 recommendations from the Report on the Review of the Narcotic Drugs Act 1967.

Report on the Review into the 2016 medicinal cannabis amendments to the Narcotic Drugs Act 1967 was tabled in Parliament on Thursday 5 September 2019.

The Australian Government will boost the nation's medicinal cannabis industry by prioritising projects that have been granted Major Project Status (MPS) and ultimately driving economic growth.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #9.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #8.

A clarification of the processing rules around the timing of a medicinal cannabis licence and narcotics manufacturing licences.

Professor John McMillan AO appointed to review and report on the operation of the Narcotic Drugs Act 1967.

The TGA will be hosting public meetings in February 2019 in Sydney, Brisbane and Melbourne.

Correcting the record on the 5 December 2016 Australian Financial Review story.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #7.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communique #6.

False and misleading claims made by some companies

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communique #5.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communique #4.

Allowing the export of Australian-manufactured medicinal cannabis products.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communique #3.

Doctors wishing to prescribe unregistered medicinal cannabis products under SAS Cat A.

Response to public consultation is now available.

Office of Drug control is seeking feedback on the potential export of medicinal cannabis.

The Australian Advisory Council on the Medicinal Use of Cannabis, Communique #2.

The Office of Drug Control will be hosting two information and consultation sessions in July 2017.

Imported medicinal cannabis products only, not domestically produced product, can now be supplied through Special Access Scheme Category A.

Unregistered medicinal cannabis products can now be prescribed under the Special Access Scheme Category A.

The total number of licences currently granted stands at 12.